MedTrace Logo

Mycophenolate Mofetil Immunosuppression Without/With Reduced Dose Calcineurin Inhibitor Long After Liver Transplantation

NCT00206076 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2013-08-02

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to assess the safety and efficacy of mycophenolate mofetil alone, or with reduced dose cyclosporine (CsA) or tacrolimus, for immunosuppression long-term after liver transplantation, in an attempt to reduce the potential side effects from using cyclosporine or tacrolimus.

Conditions

Interventions

DRUG

mycophenolate mofetil

mycophenolate mofetil and half their baseline dose of calcineurin inhibitor

DRUG

mycophenolate mofetil

mycophenolate mofetil monotherapy

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Albert Einstein Healthcare Network

    lead OTHER

Principal Investigators

  • David J Reich, MD · Drexel College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00206076 on ClinicalTrials.gov